clinical trial · NCT07680582
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
Solid TumorABO2109 InjectionToripalimab
brief summary
The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.
started
Jun 9, 2026
primary completion
Jun 30, 2026
completion
Feb 9, 2031
last updated
Jul 2, 2026
official title
An Exploratory Study of Personalized Cancer Vaccine (ABO2109) in Adjuvant Therapy of Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol